Key Dates

Related Announcements

NOT-HD-19-022 - Notice of Special Interest: Research on Emergency Medical Services for Children (EMSC)

NOT-MD-18-006 - Notice of NIMHD's Interest in the Causes, Consequences, and Prevention of Violence

NOT-MD-20-011 - Notice of Special Interest: Health Services Research on Minority Health and Health Disparities (R01- Clinical Trial Optional)

PA-18-334 - NIDCD Clinical Trials in Communication Disorders (R01 Clinical Trial Required)

PA-18-358 - NINDS Exploratory Neuroscience Research Grant (R21- Clinical Trial Optional)

PA-18-480 - NICHD Research Project Grant (R01 Clinical Trial Required)

PA-18-481 - NICHD Small Grant Program (R03 Clinical Trial Optional)

PA-18-482 - NICHD Exploratory/Developmental Research Grant (R21 Clinical Trial Optional)

PA-20-172 - Long-Term Effects of Disasters on Health Care Systems Serving Health Disparity Populations (R01- Clinical Trial Optional)

PA-20-176 - Mentored Research Scientist Development Award (Parent K01 Independent Clinical Trial Required)

PA-20-183 - Research Project Grant (Parent R01 Clinical Trial Required)

PA-20-184 - Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)

PA-20-185 - Research Project Grant (Parent R01 Clinical Trial Not Allowed)

PA-20-187 - NIH Pathway to Independence Award (Parent K99/R00 Independent Clinical Trial Required)

PA-20-188 - NIH Pathway to Independence Award (Parent K99/R00 Independent Clinical Trial Not Allowed)

PA-20-190 - Mentored Research Scientist Development Award (Parent K01 Independent Clinical Trial Not Allowed)

PA-20-191 - Mentored Research Scientist Development Award (Parent K01 Independent Basic Experimental Studies with Humans Required)

PA-20-194 - NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)

PA-20-195 - NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)

PA-20-196 - NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)

PA-20-201 - Mentored Clinical Scientist Research Career Development Award (Parent K08 Independent Basic Experimental Studies with Humans Required)

PA-20-202 - Mentored Clinical Scientist Research Career Development Award (Parent K08 Independent Clinical Trial Required)

PA-20-203 - Mentored Clinical Scientist Research Career Development Award (Parent K08 Independent Clinical Trial Not Allowed)

PA-20-204 - Mentored Patient-Oriented Research Career Development Award (Parent K23 Independent Basic Experimental Studies with Humans Required)

PA-20-205 - Mentored Patient-Oriented Research Career Development Award (Parent K23 Independent Clinical Trial Not Allowed)

PA-20-206 - Mentored Patient-Oriented Research Career Development Award (Parent K23 Independent Clinical Trial Required)

PA-20-207 - NIH Support for Conferences and Scientific Meetings (Parent R13 Clinical Trial Not Allowed)

PA-20-260 - PHS 2020 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)

PA-20-261 - PHS 2020-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Required)

PA-20-262 - PHS 2020-2 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Required)

PA-20-265 - PHS 2020-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Not Allowed)

PAR-17-264 - Innovative Mental Health Services Research Not Involving Clinical Trials (R01)

PAR-18-290 - National Cancer Institute Program Project Applications (P01 Clinical Trial Optional)

PAR-18-340 - NIDCD Cooperative Agreement for Clinical Trials in Communication Disorders (U01 - Clinical Trial Required)

PAR-18-420 - NINDS Exploratory Clinical Trials (U01 Clinical Trial Required)

PAR-18-422 - NINDS Efficacy Clinical Trials (U01 Clinical Trial Required)

PAR-18-559 - Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required)

PAR-18-869 - Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional)

PAR-19-070 - Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R01 Clinical Trial Optional)

PAR-19-071 - Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R21 Clinical Trial Not Allowed)

PAR-19-093 - Leveraging Health Information Technology (Health IT) to Address Minority Health and Health Disparities (R01 Clinical Trial Optional)

PAR-19-189 - Pilot Services Research Grants Not Involving Clinical Trials (R34 Clinical Trial Not Allowed)

PAR-19-309 - Stimulating Innovations in Behavioral Intervention Research for Cancer Prevention and Control (R21 Clinical Trial Optional)

PAR-19-367 - Maximizing Investigators' Research Award (R35 - Clinical Trial Optional)

PAR-20-052 - NCI Small Grants Program for Cancer Research for Years 2020, 2021, and 2022 (NCI Omnibus R03 Clinical Trial Optional)

PAR-20-079 - Surgical Disparities Research (R01 - Clinical Trial Optional)

PAR-20-103 - Collaborative Program Grant for Multidisciplinary Teams (RM1 - Clinical Trial Optional)

PAR-20-117 - Maximizing Investigators Research Award (MIRA) for Early Stage Investigators (R35 - Clinical Trial Optional)

PAR-20-150 - NIMHD Exploratory/Developmental Research Grant Program (R21 - Clinical Trial Optional)

RFA-MH-18-700 - Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (Collaborative R01 - Clinical Trial Required)

RFA-MH-18-701 - Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (R01 Clinical Trial Required)

RFA-MH-18-706 - Pilot Effectiveness Trials for Treatment, Preventive and Services Interventions (R34- Clinical Trial Required)

Issued by

National Institute of Neurological Disorders and Stroke (NINDS)

National Eye Institute (NEI)

National Heart, Lung, and Blood Institute (NHLBI)

National Institute on Aging (NIA)

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

National Institute on Deafness and Other Communication Disorders (NIDCD)

National Institute on Drug Abuse (NIDA)

National Institute of General Medical Sciences (NIGMS)

National Institute of Mental Health (NIMH)

National Institute on Minority Health and Health Disparities (NIMHD)

National Cancer Institute (NCI)

Purpose

Purpose

The purpose of this Notice is to announce an interest in research addressing patients with emergency medical conditions, including trauma.

Background

Over 145 million people are seen in emergency departments across the US. Emergency departments are the source of twelve million admissions, or 35% of all hospital admissions and 14% of all outpatient visits. This includes over 27 million children under the age of 15, 23 million adults over the age of 65 and over 42 million visits for injuries and major trauma. When they learn of a patient's new symptoms, primary care providers often use the emergency department to obtain rapid diagnostic tests and a treatment plan.

Emergency Departments are the only component of the country's healthcare system that is accessible at any time of the day or night, and by law they provide treatment regardless of the ability to pay. Rapid assessment and treatment within the first minutes or hours after the onset of illness plays a major role in determining both the trajectory of recovery and future healthcare costs.

Research in the emergency setting offers a unique opportunity to improve not only the treatment of acute life-threatening disorders, but also a spectrum of common disorders that encompass a considerable burden of illness and account for a major component of health care costs.

Research Objectives

This notice invites basic, translational and clinical research and career development programs that effect all areas of emergency medical care, including injury and trauma. Wherever appropriate, investigators are encouraged to utilize existing research networks, such as the NCATS supported CTSAs, NHLBI-NINDS supported SIREN emergency care research network, the NCI CONCERN oncology emergency research network, or the HRSA supported PECARN pedicatric critical care network.

IC Specific Application and Submission Information:

Applicants must select the IC and associated FOA to use for submission of an application in response to this NOSI. The selection must align with the IC requirements listed in order to be considered responsive to that FOA. Non-responsive applications will be withdrawn from consideration for this initiative. In addition, applicants using NIH Parent Announcements (listed below) will be assigned to those ICs on this NOSI that have indicated those FOAs are acceptable and based on usual application-IC assignment practices.

• PA-20-183 - Research Project Grant (Parent R01 Clinical Trial Required)
• PA-20-184 - Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
• PA-20-185 - Research Project Grant (Parent R01 Clinical Trial Not Allowed)
• PA-20-187 - NIH Pathway to Independence Award (Parent K99/R00 Independent Clinical Trial Required)
• PA-20-188 - NIH Pathway to Independence Award (Parent K99/R00 Independent Clinical Trial Not Allowed)
• PA-20-190 - Mentored Research Scientist Development Award (Parent K01 Independent Clinical Trial Not Allowed)
• PA-20-191 - Mentored Research Scientist Development Award (Parent K01 Independent Basic Experimental Studies with Humans Required)
• PA-20-194 - NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
• PA-20-195 - NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
• PA-20-196 - NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)
• PA-20-201 - Mentored Clinical Scientist Research Career Development Award (Parent K08 Independent Basic Experimental Studies with Humans Required)
• PA-20-202 - Mentored Clinical Scientist Research Career Development Award (Parent K08 Independent Clinical Trial Required)
• PA-20-203 - Mentored Clinical Scientist Research Career Development Award (Parent K08 Independent Clinical Trial Not Allowed)
• PA-20-204 - Mentored Patient-Oriented Research Career Development Award (Parent K23 Independent Basic Experimental Studies with Humans Required)
• PA-20-205 - Mentored Patient-Oriented Research Career Development Award (Parent K23 Independent Clinical Trial Not Allowed)
• PA-20-206 - Mentored Patient-Oriented Research Career Development Award (Parent K23 Independent Clinical Trial Required)
• PA-20-207 - NIH Support for Conferences and Scientific Meetings (Parent R13 Clinical Trial Not Allowed)
• PA-20-260 - PHS 2020 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)
• PA-20-261 - PHS 2020-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Required)
• PA-20-262 - PHS 2020-2 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Required)
• PA-20-265 - PHS 2020-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Not Allowed)

All instructions in the SF424 (R&R) Application Guide and the funding opportunity announcement used for submission must be followed, with the following additions:

• For funding consideration, applicants must include NOT-NS-20-005 (without quotation marks) in the Agency Routing Identifier field (box 4B) of the SF424 R&R form. Applications without this information in box 4B will not be considered for this initiative

Applications nonresponsive to terms of this NOSI will be withdrawn from consideration for this initiative.

National Cancer Institute (NCI)

NCI is interested in observational and multilevel intervention studies focused on health-related outcomes in patients with cancer utilizing emergency care services. Interest includes care of patients during active treatment and throughout cancer survivorship.

Research projects may include but are not limited to:

• Cancer-related utilization of emergency care and the patient, caregiver, clinician, and delivery system factors that drive emergency service use

• Risk stratification, risk prediction models, and evidence-based strategies to improve health-related outcomes in the cancer population utilizing emergency services

• Care delivery models and interventions to reduce emergency care use

NCI's FOAs for this NOSI include the following or their subsequent reissued equivalents:

*See below for NCI-specific contact information for PAR-20-052 only.

National Eye Institute (NEI)

Patients present in the Emergency Departments (EDs) with a variety of ocular and/or visual system disorders with symptoms ranging from mild discomfort to severe pain and/or sudden vision loss. The etiology of these symptoms may be the result of infection, inflammation, trauma, glaucoma related to sudden angle closure, retinal detachments, or other causes that could result in permanent vision loss if not treated immediately and with a proper standard of care. Often the treatment for these conditions requires the expertise and specialized facilities of eye care professionals. Immediate referral consultation may be available in EDs in more urban areas but can be delayed for a day or longer in more rural settings. Relief of symptoms and preservation of vision critically depends on accurate diagnosis, early treatment protocols to stabilize the condition and prevent further damage, and an understanding of the urgency to be evaluated and treated by an eye care specialist. The NEI is interested in research and education that will advance the provision of eye care in EDs in order to maximize the preservation of vision of patients that is threatened by injury or disease. Examples of topics include but are not limited to:

• Telemedicine approaches including equipment and consultation approaches that can bring eye care specialists into the ED remotely to assist in diagnosis and treatment
• Epidemiological studies to understand the nature of eye emergencies presented in EDs and disparities in their outcomes in rural versus urban areas
• Educational programs and conferences provided by eye care specialists and aimed at providing ED personnel with the essentials of diagnosis, early treatment, and understanding of the urgency of care

NEI's FOAs for this NOSI include the following or their subsequent reissued equivalents:

National Heart Lung and Blood Institute (NHLBI)

NHLBI is interested in studies of basic, translational, and clinical research that affect all areas of emergency medical care related to heart, lung, and blood diseases, including injury and trauma, focusing on various stages of science relevant to emergency care which may or may not lead to clinical trials. The emergency would be defined by unstable cardiopulmonary/hematologic state requiring emergency care in the pre-hospital, ED, or intensive care setting.

Research projects may include but are not limited to:

• Novel management of acute emergencies, such as acute respiratory failure, pulmonary embolus, asthma or COPD exacerbation, pneumothorax, pneumonia, myocardial infarction, cardiac arrest, coagulopathy of trauma, DIC, TBI-related coagulation abnormalities, and medical emergencies associated with acute thrombotic conditions, such as PE and ischemic stroke.
• Basic, translational, and clinical research programs that affect all aspects of emergency care related to cardiopulmonary, hematologic, and sleep disease.
• Rapid assessment and treatment of acute, potentially fatal conditions in the ED related to cardiopulmonary, hematologic, and sleep disease, which may include pre-hospital original and initial care.
• Risk stratification, predictive models to be applied in the ED to related to cardiopulmonary, hematologic, and sleep disease to improve outcomes.
• ED and pre-hospital-based delivery models and interventions related to cardiopulmonary, hematologic, and sleep disease to streamline ED care for these conditions.
• Clinical management potentially leading to clinical practice guideline development and/or guideline utilization to improve the outcomes of patients with cardiopulmonary and hematologic emergencies.

NHLBI's FOAs for this NOSI include the following or their subsequent reissued equivalents:

National Institute on Aging (NIA)

Of the 143 million annual visits to U.S. Emergency Departments (ED), >23 mill are by adults >65 yrs; the rate and frequency of annual ED visits increases with advancing age (average of 5 visit/yr in those over 85 yrs old). Older adults are more vulnerable to acute illnesses and trauma and have worse outcomes than younger adults. Aging changes and multiple chronic conditions often alter presenting symptoms and make diagnoses and treatment more challenging. Furthermore, the loud, fast-paced environment in ED can magnify confusion and cognitive function, especially when underlying cognitive and/or functional impairment exist. Additional areas impacting older adults presenting for emergent care include polypharmacy, frequent return visits, identifying a safe disposition, social factors and end-of-life considerations.

Research projects may include but are not limited to:

• Development of strategies to improve the diagnoses, prognoses, management and outcomes of emergent condition in older adults.
• Improved triage, assessment, prognoses, management and outcome of geriatric trauma including motor vehicle accidents (issues pertaining to older drivers).
• Reduction in complications due to medication use in older adults including polypharmacy, increased adverse events, medication reconciliation.
• Research focused on prevention, identification, management outcomes of common geriatric syndromes including falls, cognitive impairment, delirium, multiple chronic condition, and/or functional decline.
• Identification and management of elder abuse, suicide risk/prevention and/or substance abuse.
• Management of pain and/or palliative care in older adults.
• Strategies to reduce frequent and/or prompt recidivism (recurrent ED revisits) including employing paramedicine, telemedicine and alternative settings to pre-empt ED visits and/or to provide a safe disposition for older adults.
• Improvement in communication involving primary care providers, caregivers, specialists, hospital staff.
• Recognition and management strategies of persons with cognitive impairment with emergent conditions including addressing possible environmental and providers contributors.
• Addressing advance care planning and end-of-life care in the setting of emergent medical issues and/or trauma.

NIA's FOAs for this NOSI include the following or their subsequent reissued equivalents:

National Institute on Alcohol Abuse and Alcoholism

Alcohol use is associated with high levels of morbidity and mortality. Emergency departments (EDs) admissions have disproportionate numbers of individuals presenting under the influence of alcohol or with alcohol misuse problems, including those under the age of 21. In addition, the rate of visits may vary by gender (mostly male) and race/ethnicity (Blacks, Hispanics). As with trauma facilities, EDs can seize upon a teachable moment to help non-treatment seeking individuals modify harmful behavior(s). The benefits of providing screening, initial intervention, and referral to further care for alcohol misuse in the ED may provide a valuable prolonged impact on health. In light of the current economy and protracted COVID-19 pandemic (e.g., unemployment rates affecting families), the lack of affordable health care, and reliance on the ED as a primary care locality, such interventions will be critical. Prior work has shown that screening and brief interventions in ED settings can be accomplished. However, early findings are mixed regarding intervention efficacy and successful referral to treatment. Further inquiry is critical for developing better interventions and determining whether reductions in alcohol-related consequences are accompanied by reductions in consumption levels and patterns of use, cost-effectiveness, implementation and sustainability, and longer-term evaluations of adherence and outcomes from referral(s) to higher levels of care. Examples of research topics include, but are not limited to, investigations that:

• Determine the range of specific types of alcohol-related problems and for whom (e.g., uninsured; health disparities) ED screening and interventions should target for purposes of identifying specific types of interventions.
• Develop innovative approaches to screening, brief interventions, and referrals to treatment in individuals with alcohol misuse in ED.
• Investigate the integration of brief interventions in routine ED health care. What are the barriers to successful integration or implementation of interventions? What technological innovations, managerial practices, or other strategies facilitate the implementation or adoption of interventions and referral practices?
• Evaluate specific components of interventions (e.g., motivational enhancement or simple feedback and advice to even medications) to determine which components are most effective in the ED setting. Such analyses could clarify whether intervention effectiveness depends on the patients readiness to change and/or the severity of their injury or illness, whether boosters are beneficial and cost-effective, whether follow-up and boosters should be conducted by phone or in person, or whether self-reported outcomes should be obtained by smart phone in person, or by interactive voice response.
• Determine elements related to successful referral to treatment, translation into standard clinical practice, and dissemination and implementation of effective interventions.
• Examine moderators of ED intervention efficacy (e.g., injury/non-injury ED visits; comorbidity) and maintenance of longer-term outcomes.
• Assess screening, brief interventions, and referral to treatment for the spectrum of alcohol misuse in the context of culturally diverse groups and non-English-speaking patients in the ED.

NIAAA's FOAs for this NOSI include the following or their subsequent reissued equivalents:

National Institute of Child Health and Human Development (NICHD)

NICHD is interested in studies of basic, translational, and clinical research in pediatric trauma care and emergency medical services to children

Most children receive emergency care in general hospitals, which are less likely to have pediatric expertise, equipment, and policies in place for the care of children. Children make up 27 percent of all ED visits, but only 6 percent of EDs in the U.S. have all the necessary supplies for pediatric emergencies. Many drugs and medical devices have not been adequately tested on, or dosed properly for children.

Children are different from adults in their patterns of use of health services, in their distinctive developmental vulnerabilities and strengths, and in their dependence on others for access to care and financial resources. The same is true in children's emergency care. Research in emergency medical services for children (EMSC) is essential to validate the clinical merit of care that is given, to identify better kinds of care, to devise better ways to deliver that care, and to learn where best to direct prevention activities.

Research and training projects may include but are not limited to:

Studies to improve diagnosis (including the use of decision trees and diagnostic aids), treatment, and health outcomes of children receiving EMSC.

Studies to improve diagnosis, reporting, treatment, and follow up of child abuse or neglect and youth violence through programs instituted in emergency departments or in pre-hospital care.

Studies utilizing syndromic surveillance in the emergency department setting as an aid for tracking childhood injuries including inflicted neurotrauma, violence related injuries, child physical and sexual abuse, or injuries sustained from motor vehicle crashes

Studies examining the outcomes of emergency care for children acutely ill secondary to infection, trauma, or acute exacerbation of chronic illness.

The biobehavioral aspects of pain, stress, and coping with illness or injury in situations of emergency care.

Studies examining disparities in EMSC for children by geographic region, race/ethnicity or SES.

Studies to determine the most effective therapeutic and management strategies for injured and acutely ill children and the necessary emergency services to enhance survival and minimize disability.

In addition to this NOSI, NICHD also supports Emergency Medicine Research through NOT-HD-19-022 "Notice of Special Interest: Research on Emergency Medical Services for Children (EMSC)"

NICHD's FOAs for this Notice include the following or their subsequent reissued equivalents:

National Institute on Drug Abuse (NIDA)

NIDA is invested in emergency medicine research in the areas of diagnosis, prevention, treatment, and implementation of medical, behavioral, nursing, and paramedical strategies to fight the drug abuse epidemic that is devastating the country. Emergency medicine research is not the only explored at emergency departments (ED) but also non-medical areas in which emergencies due to drug use might occur, where ambulances and paramedical services are fundamental.

Research projects may include but are not limited to:

• Pharmacological methods to prevent and treat drug overdose before and after reaching the ED;
• Basic and clinical research related to toxicity associated with substance use such as vaping lung injury, cannabis withdrawal syndrome, psychoses, stroke, cardiac arrythmia , and others;
• Prevention and treatment of suicide in relation to drug abuse;
• Novel pharmacological products for treating acute opioid, fentanyl, methamphetamine, sedatives, cocaine, amphetamines, marijuana, vaping intoxications;
• Linkage to- and continuation of care after drug abuse related ED visits;
• Initiation of opioid use treatments in the ED (e.g., long-acting buprenorphine or naltrexone); research into resuscitation devices and monitoring; combination strategies of treatment and resuscitation for polydrug abuse; warning device studies with mobile-technology; geo-medicine to intervene for potential patients at risk (clubs, megaevents, vulnerable neighborhoods, schools, fraternities and sororities, train and bus stations);
• Rapid laboratory detection of various illicit drugs;
• Prevention and treatment of the consequences of violence and drug abuse in the ED;
• ED detection, rapid testing and initial therapeutic intervention, treatment, and implementation strategies for the syndemic of drug abuse, HIV and hepatitis-C.

NIDA's FOAs for this NOSI include the following or their subsequent reissued equivalents:

National Institute on Deafness and Other Communication Disorders (NIDCD)

NIDCD encourages translational and clinical studies evaluating the diagnosis, treatment, and management of disorders that cover the scientific mission areas of hearing, balance, taste, smell, voice, speech, and language in the setting of emergency and acute care medicine. Studies evaluating barriers to care and disparities in health-related and patient-centered outcomes for individuals with hearing loss and those with communication disorders treated in this setting are also encouraged. Studies emphasizing recruitment of underrepresented minorities will be prioritized. Areas of scientific interest include but are not limited to:

• Streamlined, improved diagnosis and management with an emphasis on reducing healthcare costs and improving patient outcomes for:
  • vestibular-related dizziness and vertig
  • sudden-onset hearing loss
• Development of diagnostic interventions that can be feasibly utilized in the Emergency Department (ED) setting to rapidly and accurately differentiate benign versus life-threatening causes of vertigo.
• Advancements in clinical management of patients seen in the ED leading to more prompt provision of treatment resulting in improved outcomes of hearing, voice, speech, or language.
• The impact of hearing loss and communication disorders on the diagnosis, management, and health outcomes of individuals seen for care in the ED or similar acute care setting

NIDCD's FOAs for this NOSI include the following or their subsequent reissued equivalents:

National Institute of General Medicine Sciences (NIGMS)

NIGMS will consider funding basic and clinical mechanistic research studies of the biochemical and physiological changes induced by injury and critical illness, with examination of inflammatory and immune responses, hypermetabolism, and prediction of body-wide recovery. Research areas of interest include:

• Injury (traumatic, thermal, or surgical) from the post-injury period to acute phase through long-term effects, until recovery or mortality.
• Sepsis and septic shock. Please see NOT GM 19-054, NIGMS Priorities for Sepsis Research.
• Processes underlying wound healing, tissue repair, and regeneration in critically ill patients.

NIGMS's FOAs for this NOSI include the following or their subsequent reissued equivalents:

National Institute of Mental Health (NIMH)

NIMH supports research in ED settings that aligns closely to Strategic Goal of the NIMH Strategic Plan: https://www.nimh.nih.gov/about/strategic-planning-reports/goal-4-strengthen-the-public-health-impact-of-nimh-supported-research.shtml. Emergency care is a critical care point for suicide prevention: Nearly half of suicide decedents visit emergency care in the year before death, and around one-fifth in the 2 months before death. These rates are substantially higher than for the general population and underscore the potential value of improving identification and treatment of suicide risk in emergency departments (EDs). Suicide risk is also increased after ED discharge to the community. NIMH is particularly interested in suicide prevention efforts that are scalable, including telehealth. Research topics may include but are not limited to:

• Evaluating ED-administered assessments intended to identify targets for brief, personalized ED-based interventions
• Testing suicide prevention ED workflows for screening, assessment, brief interventions such as safety planning, and facilitated referral/ treatment engagement (in person or by telehealth)
• Testing strategies that provide psychotherapeutic services during boarding times for patients waiting for inpatient care
• Testing post discharge approaches that maintain contact for protection against relapse (e.g., caring contacts via text, email, mail)
• Testing post discharge approaches to enhance linkage to care (e.g., primary care; outpatient specialty care), and continuation of care after suicide risk related ED visits.
• Developing and testing strategies to reduce economic, racial, and other disparities in the processes of suicide risk identification, provision of ED-based interventions, and referral to and uptake of post-discharge treatment
• Evaluating and testing the adequacy of existing or new mechanisms to finance the provision of evidence-based services
• Testing the potential benefits of diversion efforts for high risk individuals without injuries (e.g. use of community crisis services as an alternative to an ED visit)
• Developing, validating, and refining models and the role of ED services for determining the optimal level of care across the care continuum (e.g., LOCUS approach for persons with Serious Mental Illness

NIMH's FOAs for this NOSI include the following or their subsequent reissued equivalents:

For research on the effectiveness of interventions or services, NIMH supports studies that employ an experimental therapeutics approach, whereby clinical trials are designed not only to test the intervention effects on outcomes of interest, but also to inform understanding of the intervention’s mechanisms of action. As such, applications that propose to develop and/or test the efficacy/effectiveness of preventive, therapeutic or services interventions must include specification of the intervention target(s)/mechanism(s) and assessment of intervention-induced changes in the presumed target mechanism(s) that are hypothesized to account for the intervention outcome. See the Support for Clinical Trials at NIMH web page for additional information regarding dedicated Funding Opportunity Announcements (FOAs) for NIMH clinical trials research support.

NIMH's FOAs for this NOSI also include the following or their subsequent reissued equivalents:

National Institute on Minority Health and Health Disparities (NIMHD)

NIMHD is interested in observational and multilevel intervention studies focused on health-related outcomes in patients from populations with health disparities utilizing emergency care services. NIH-designated U.S. health disparity populations include Blacks/African Americans, Hispanics/Latinos, American Indians/Alaska Natives, Asian Americans, Native Hawaiians and other Pacific Islanders, socioeconomically disadvantaged populations, underserved rural populations, and sexual and gender minorities.

Research projects may include but are not limited to:

• Research to examine how the structure and organization of health care systems serving populations with health disparities impact emergency services utilization and health outcomes
• Multi-level or multi-factorial assessments of timing (including patients or relatives first realization of condition/symptoms) and timeliness of health care system response (including ambulance and emergency medical services in transit to an emergency department or hospital) and emergency care delivery between onset of condition/symptoms, especially in remote or low-income settings and for patients for English is not their primary language, and potential interventions to overcome any barriers identified.
• Risk stratification, risk prediction models, and evidence-based strategies to improve health-related outcomes in the populations with health disparities utilizing emergency services
• Rapid assessment and treatment of acute, potentially fatal condition in the ED (and/or the pre-hospital or initial care setting), especially for patients from socioeconomically disadvantaged backgrounds living in remote locations or who have multiple chronic health conditions.
• Patient, caregiver, clinician, and health care system factors that drive emergency service use [including but not limited to seeking health care for established chronic conditions or their exacerbations, mental health, trauma/injury (including self-inflicted), violence (including intimate partner violence, gender-based violence or racial/ethnic-based violence and bullying), pain, and drug use disorders].
• Health care delivery models and interventions (including health care coordination) to reduce emergency care use
• Research to assess and understand conscious and unconscious bias or lack of cultural competency of health care providers and other actors (including pre-ED or pre-hospital services) providing emergency services to patients from populations with health disparities, as well as interventions to reduce these biases, improve cultural competence, and how these interventions impact quality of care, improve patients health outcomes and reduce health disparities.
• Research that informs on and evaluates the impact of changes in local, state, and federal health care and non-health care environments policies on emergency service utilization and health outcomes (e.g., laws/policies regarding insurance coverage, eligibility for services, workplace safety, sick leave).

In addition to this NOSI, NIMHD supports research on Emergency Medicine through NOT-MD-20-011 "Notice of Special Interest: Health Services Research on Minority Health and Health Disparities (R01- Clinical Trial Optional)" and NOT-MD-18-006 "Notice of NIMHD's Interest in the Causes, Consequences, and Prevention of Violence"

NIMHD's FOAs for this NOSI include the following or their subsequent reissued equivalents:

National Institute of Neurological Disorders and Stroke (NINDS)

The National Institute of Neurological Disorders and Stroke invites clinical studies to improve the care of patients with neurological emergencies. These include, but are not limited to:

• Altered mental status and coma
• Cerebrovascular emergencies (acute stroke, ICH, SAH,)
• Headache and migraine
• Meningitis and encephailits
• Seizures and status epilepticus
• Traumatic brain injury
• Serotonin syndrome,
• Neuroleptic malignant syndrome
• Dystonic storm
• Spinal cord emergencies (traumatic and nontraumatic)
• Acute management of increased ICP
• Neuromuscular emergencies (including peripheral nerve, neuromuscular junction, and muscle) especially those that result in acute respiratory failure
• Myasthenic crisis
• Guillain Barre with respiratory compromise
• ALS/motor neuron disease with respiratory failure

NINDS has established networks to facilitate the conduct of multi-center clinical trials in selected neurological disorders (StrokeNet, NeuroNext and SIREN). We encourage research that includes participants across the age spectrum. NINDS expects clinical trials to have an appropriate balance of gender, diverse and minority populations, and age of the subjects enrolled. Investigators should use Common Data Elements whenever possible.

Investigators planning multi-center clinical trials are strongly advised to contact NINDS at least 6 months in advance of a planned submission to determine the appropriate funding mechanism for their application.

NINDS's FOAs for this NOSI include the following or their subsequent reissued equivalents:

Application and Submission Information

This notice applies to due dates on or after October 5, 2020 and subsequent receipt dates through September 8, 2022.

Submit applications for this initiative using one of the following funding opportunity announcements (FOAs) or any reissues of these announcement through the expiration date of this notice:

• PA-18-334 - NIDCD Clinical Trials in Communication Disorders (R01 Clinical Trial Required)
• PA-18-358 - NINDS Exploratory Neuroscience Research Grant (R21- Clinical Trial Optional)
• PA-18-480 - NICHD Research Project Grant (R01 Clinical Trial Required)
• PA-18-481 - NICHD Small Grant Program (R03 Clinical Trial Optional)
• PA-18-482 - NICHD Exploratory/Developmental Research Grant (R21 Clinical Trial Optional)
• PA-20-172 - Long-Term Effects of Disasters on Health Care Systems Serving Health Disparity Populations (R01- Clinical Trial Optional)
• PA-20-176 - Mentored Research Scientist Development Award (Parent K01 Independent Clinical Trial Required)
• PA-20-183 - Research Project Grant (Parent R01 Clinical Trial Required)
• PA-20-184 - Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
• PA-20-185 - Research Project Grant (Parent R01 Clinical Trial Not Allowed)
• PA-20-187 - NIH Pathway to Independence Award (Parent K99/R00 Independent Clinical Trial Required)
• PA-20-188 - NIH Pathway to Independence Award (Parent K99/R00 Independent Clinical Trial Not Allowed)
• PA-20-190 - Mentored Research Scientist Development Award (Parent K01 Independent Clinical Trial Not Allowed)
• PA-20-191 - Mentored Research Scientist Development Award (Parent K01 Independent Basic Experimental Studies with Humans Required)
• PA-20-194 - NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
• PA-20-195 - NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
• PA-20-196 - NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)
• PA-20-201 - Mentored Clinical Scientist Research Career Development Award (Parent K08 Independent Basic Experimental Studies with Humans Required)
• PA-20-202 - Mentored Clinical Scientist Research Career Development Award (Parent K08 Independent Clinical Trial Required)
• PA-20-203 - Mentored Clinical Scientist Research Career Development Award (Parent K08 Independent Clinical Trial Not Allowed)
• PA-20-204 - Mentored Patient-Oriented Research Career Development Award (Parent K23 Independent Basic Experimental Studies with Humans Required)
• PA-20-205 - Mentored Patient-Oriented Research Career Development Award (Parent K23 Independent Clinical Trial Not Allowed)
• PA-20-206 - Mentored Patient-Oriented Research Career Development Award (Parent K23 Independent Clinical Trial Required)
• PA-20-207 - NIH Support for Conferences and Scientific Meetings (Parent R13 Clinical Trial Not Allowed)
• PA-20-260 - PHS 2020 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)
• PA-20-261 - PHS 2020-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Required)
• PA-20-262 - PHS 2020-2 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Required)
• PA-20-265 - PHS 2020-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Not Allowed)
• PAR-17-264 - Innovative Mental Health Services Research Not Involving Clinical Trials (R01)
• PAR-18-290 - National Cancer Institute Program Project Applications (P01 Clinical Trial Optional)
• PAR-18-340 - NIDCD Cooperative Agreement for Clinical Trials in Communication Disorders (U01 - Clinical Trial Required)
• PAR-18-420 - NINDS Exploratory Clinical Trials (U01 Clinical Trial Required)
• PAR-18-422 - NINDS Efficacy Clinical Trials (U01 Clinical Trial Required)
• PAR-18-559 - Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required)
• PAR-18-869 - Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional)
• PAR-19-070 - Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R01 Clinical Trial Optional)
• PAR-19-071 - Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R21 Clinical Trial Not Allowed)
• PAR-19-093 - Leveraging Health Information Technology (Health IT) to Address Minority Health and Health Disparities (R01 Clinical Trial Optional)
• PAR-19-189 - Pilot Services Research Grants Not Involving Clinical Trials (R34 Clinical Trial Not Allowed)
• PAR-19-309 - Stimulating Innovations in Behavioral Intervention Research for Cancer Prevention and Control (R21 Clinical Trial Optional)
• PAR-19-367 - Maximizing Investigators' Research Award (R35 - Clinical Trial Optional)
• PAR-20-052 - NCI Small Grants Program for Cancer Research for Years 2020, 2021, and 2022 (NCI Omnibus R03 Clinical Trial Optional)
• PAR-20-079 - Surgical Disparities Research (R01 - Clinical Trial Optional)
• PAR-20-103 - Collaborative Program Grant for Multidisciplinary Teams (RM1 - Clinical Trial Optional)
• PAR-20-117 - Maximizing Investigators Research Award (MIRA) for Early Stage Investigators (R35 - Clinical Trial Optional)
• PAR-20-150 - NIMHD Exploratory/Developmental Research Grant Program (R21 - Clinical Trial Optional)
• RFA-MH-18-700 - Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (Collaborative R01 - Clinical Trial Required)
• RFA-MH-18-701 - Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (R01 Clinical Trial Required)
• RFA-MH-18-706 - Pilot Effectiveness Trials for Treatment, Preventive and Services Interventions (R34- Clinical Trial Required)

All instructions in the SF424 (R&R) Application Guide and the funding opportunity announcement used for submission must be followed, with the following additions:

For funding consideration, applicants must include NOT-NS-20-005 (without quotation marks) in the Agency Routing Identifier field (box 4B) of the SF424 R&R form. Applications without this information in box 4B will not be considered for this initiative.

Applications nonresponsive to terms of this NOSI will not be considered for the NOSI initiative.

Inquiries

Jeremy Brown, MD
Office of Emergency Care Research
National Institute of Neurological Disorders and Stroke (NINDS)
Telephone: 301-827-8375
E-mail: [email protected]

*For PAR-20-052 - NCI Small Grants Program for Cancer Research for Years 2020, 2021, and 2022 (NCI Omnibus R03 Clinical Trial Optional) please see http://www.cancer.gov/researchandfunding/contacts for Scientific/Research Contacts at NCI.

For all other NCI related FOAs on this NOSI:

Nonniekaye Shelburne MS, CRNP, AOCN
National Cancer Institute (NCI)
Telephone: 240-276-6897
Email: [email protected]

Don Everett, M.A.
National Eye Institute (NEI)
Phone: (301) 451-2020
Email: [email protected]v

Susan Zieman, M.D., Ph.D.
National Institute on Aging (NIA)
Telephone: 301-496-6761
E-mail: [email protected]

Mariela C. Shirley, Ph.D
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Telephone: 301-402-9389
Email: [email protected]

Dr. Valerie Maholmes
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Telephone: 301-496-1514
E-mail: [email protected]

Raul N. Mandler, MD; FAAN; FANA
National Institute on Drug Abuse (NIDA)
Telephone: 301-480-2541
E-mail: [email protected]

Kelly King, Au.D., Ph.D.
National Institute on Deafness and Other Communication Disorders (NIDCD)
Telephone: 301-402-3458
Email: [email protected]

George Sopko, M.D.
National Heart, Lung and Blood Institute (NHLBI)
Telephone: 301-435-0504
Email: [email protected]

Xiaoli Zhao, Ph.D.
National Institute of General Medical Sciences (NIGMS)
Email: [email protected]

Stephen O'Connor, Ph.D.
National Institute of Mental Health (NIMH)
Telephone: (301) 480-8366
E-mail: [email protected]

Benyam Hailu, MD
National Institute on Minority Health and Health Disparities (NIMHD)
Telephone: 301-594-8696
E-mail: [email protected]